Prevalence of chronic rhinosinusitis without/with nasal polyps according to severity in Spain
Rhinology Journal · 01.06.2024 · 0-0
DOI: 10.4193/rhin23.341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rhinology Journal, online erschienen am 01.06.2024. Verfasst von J Mullol und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Universitat de Barcelona, FRCB-IDIBAPS, CIBERES, Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Severity of Illness Index. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
The worldwide prevalence range of chronic rhinosinusitis (CRS) is 5-12%; from this, 20 % have nasal polyps. Due to the little epidemiological data about CRS in the Spanish population, this study analyses the prevalence and severity of CRS with (CRSwNP) or without (CRSsNP) nasal polyps, and their connection with other coexisting type 2 inflammatory diseases in Spain. Methodology: This is a retrospective, large-scale, nationwide, epidemiological study based on the electronic medical records from the BIG-PAC® database. Patients diagnosed of CRSsNP and CRSwNP were identified using specific disease codes. The severe form of the disease was defined as patients who received at least a long course of antibiotics in CRSsNP or ≥2 short courses of systemic corticosteroids in CRSwNP in ≤12 months during the last 2 years, and/or had previous sinus surgery. Physician-diagnosed prevalence, sociodemographic and clinical characteristics, and disease severity were assessed.
Results
Out of a cohort of 1,012,257 patients (≥18 years old), 42,863 and 7,550 patients with diagnosed CRSsNP and CRSwNP, respectively, were analysed. The overall prevalence of diagnosed CRS was 5.1%, being 4.3% and 0.8% for CRSsNP and CRSwNP, respectively. Patients with CRSwNP and severe forms of the disease were older and had higher levels of type 2 inflammatory biomarkers than CRSsNP patients and non-severe disease.
Conclusions
Although CRSsNP was more prevalent than CRSwNP, the severe forms of CRS were more frequent in patients with CRSwNP. In addition, CRSwNP patients had a higher incidence of coexisting type 2 inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Universitat de Barcelona, FRCB-IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
- Department of Allergology, Fundacion Jimenez Diaz, CIBER de Enfermedades Respiratorias (CIBERES), Facultad de Medicina, Universidad Autonoma de Madrid, Madrid, Community of Madrid, Spain.
- Department of Allergology, La Paz University Hospital, Institute for Health Research (IdiPAZ), Madrid, Community of Madrid, Spain.
- Asthma Unit, La Coruna University Hospital, La Coruna, Galicia, Spain.
- Department of Respiratory Medicine, Hospital Universitari Dexeus, Barcelona, Catalonia, Spain.
- Rhinology and Skull Base Unit, ENT Department, Hospital Clinic, Universitat de Barcelona, FRCB-IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
Zitieren
APA
Mullol, J., Sastre, J., Dominguez-Ortega, J., Blanco-Aparicio, M., Castillo Vizuete, J. A., Alobid, I., Garcia-Vitoria, M., & Palomo-Jimenez, P. I. (2024). Prevalence of chronic rhinosinusitis without/with nasal polyps according to severity in Spain. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin23.341
Vancouver
Mullol J, Sastre J, Dominguez-Ortega J, Blanco-Aparicio M, Castillo Vizuete JA, Alobid I, et al. Prevalence of chronic rhinosinusitis without/with nasal polyps according to severity in Spain. Rhinology Journal. 2024;0(0):0-0. doi:10.4193/rhin23.341
BibTeX
@article{Mullol2024,
author = {Mullol, J and Sastre, J and Dominguez-Ortega, J and Blanco-Aparicio, M and Castillo Vizuete, J A and Alobid, I and Garcia-Vitoria, M and Palomo-Jimenez, P I},
title = {Prevalence of chronic rhinosinusitis without/with nasal polyps according to severity in Spain},
journal = {Rhinology Journal},
year = {2024},
volume = {0},
number = {0},
pages = {0--0},
doi = {10.4193/rhin23.341}
}
EUVIMED